Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674877 | 0.84 | LPAR2 (0.34) | LPAR2LPAR3 | |
| SCHEMBL12306859 | 0.82 | LPAR2 (0.33) | LPAR2LPAR3 | |
| SCHEMBL1559671 | 0.77 | LPAR2 (0.35) | LPAR2LPAR3 | |
| SCHEMBL12306857 | 0.76 | BTN3A1 (0.38) | LPAR2LPAR3 | |
| SCHEMBL6313775 | 0.76 | OTC (0.30) | — | |
| SCHEMBL1576765 | 0.75 | — | — | |
| SCHEMBL2458254 | 0.74 | — | — | |
| SCHEMBL7633961 | 0.73 | FDPS (0.43) | LPAR2LPAR3 | |
| SCHEMBL28636538 | 0.72 | — | — | |
| SCHEMBL9891091 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017596-B2 | Phosphonates useful as modulators of T-γ-9-δ-2 activity | INNATE PHARMA, S.A. (FR) | 2011-09-13 | — | — | US | disclosed |
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | INNATE PHARMA, S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-20100204184-A1 | Phosphonates useful as modulators of T-gamma-9-delta-2 activity | LABORATOIRES MAYOLY SPINDLER (FR) | 2010-08-12 | — | — | US | disclosed |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | INNATE PHARMA S.A. (FR) | 2010-07-29 | — | — | US | disclosed |
| WO-2010049438-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS FOR THE TREATMENT OF DISEASES | INNATE PHARMA (FR) | 2010-05-06 | — | — | WO | disclosed |
| EP-1569656-B1 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2010-03-03 | — | — | EP | disclosed |
| EP-2150258-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | Innate Pharma S.A. (FR) | 2010-02-10 | — | — | EP | disclosed |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | INNATE PHARMA, S.A. (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20090304688-A1 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators | INNATE PHARMA S.A. (FR) | 2009-12-10 | — | — | US | disclosed |
| EP-2083830-A1 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | Innate Pharma (FR) | 2009-08-05 | — | — | EP | disclosed |
| US-20070134273-A1 | Composition and method for the treatment of carcinoma | ROMAGNE FRANCOIS | 2007-06-14 | — | — | US | disclosed |
| WO-2007057440-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007039635-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | INNATE PHARMA (FR) | 2007-04-12 | — | — | WO | disclosed |
| EP-1720567-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | Innate Pharma (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-20060241087-A1 | Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity | MONTERO JEAN-LOUIS | 2006-10-26 | — | — | US | disclosed |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | INNATE PHARMA, S.A.S. (FR) | 2006-08-31 | — | — | US | disclosed |
| WO-2006067635-A2 | USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT | INNATE PHARMA S.A. (FR) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005077411-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | INNATE PHARMA (FR) | 2005-08-25 | — | — | WO | disclosed |
| EP-1453840-A1 | PHOSPHONATES USEFUL AS MODULATORS OF T-GAMMA-9-DELTA-2 LYMPHOCYTE ACTIVITY | Laboratoire Mayoly Spindler (FR) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003050128-A1 | PHOSPHONATES USEFUL AS MODULATORS OF T $G(G)9$G(D)2 LYMPHOCYTE ACTIVITY | LABORATOIRE MAYOLY SPINDLER (FR) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | IFNG, IL2, ICOS | LPAR2 1444/4885LPAR3 1385/4885 |
| US-20100204184-A1 | Phosphonates useful as modulators of T-gamma-9-delta-2 activity | CD4, PRKCD, PRKCZ | LPAR2 658/4885LPAR3 1260/4885 |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | CD4, CD74, TP53 | LPAR2 1894/4885LPAR3 1706/4885 |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | IL2, IL2RA, CD4 | LPAR2 580/4885LPAR3 1798/4885 |
| US-20070134273-A1 | Composition and method for the treatment of carcinoma | IFNG, IL2, PBK | LPAR2 1931/4885LPAR3 1462/4885 |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | IFNG, IL2, ICOS | LPAR2 1736/4885LPAR3 1486/4885 |
| US-20090304688-A1 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators | CD4, FCGR3B, IFNG | LPAR2 982/4885LPAR3 830/4885 |
| US-20060241087-A1 | Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity | CD4, GNG2, PLCG2 | LPAR2 331/4885LPAR3 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.